The National Center is “here to stay”

Joined alongside an international panel of speakers, Prof Rizzuto acknowledged that when considering the idea of a cure we often perceive rare diseases as orphans, abandoned, forgotten, or left behind from medicine. He reminds us that what we consider common diseases, like cancer, are rare in that they can be broken down into subgroups for specific targets, and thus treated through personalized medicine. The conundrum of this perception is that the enormous cost of developing specific targets lies in refining the delivery methods of medicines through a common platform. This sustainable approach is where the National Center excels, as the possibility of developing drugs based on RNA technology lies in various types of RNA that can make, modify, inhibit, or change the activities of proteins within the genome path.